You're certainly a glass half full guy.
IMU has been targeting rare indications because their "me-too" drugs either:
- can't compete against the big boys already approved in the larger markets (HER-VAXX, PD1-VAXX)
- aren't as advanced and playing catch up against other clinical opportunities (Azercel).
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.1¢ |
Change
-0.001(8.33%) |
Mkt cap ! $82.13M | |||
| Open | High | Low | Value | Volume |
| 1.2¢ | 1.3¢ | 1.1¢ | $376.2K | 32.83M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 21 | 3534042 | 1.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.2¢ | 11298051 | 21 |
View Market Depth
| Last trade - 16.10pm 25/06/2025 (20 minute delay) ? |
| IMU (ASX) Chart |